Serum Institute of India Pvt Ltd.
- Country
- 🇮🇳India
- Ownership
- Subsidiary
- Established
- 1996-01-01
- Employees
- 1K
- Market Cap
- -
Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults
- Conditions
- Prevention of Malaria Transmission and Clinical Malaria
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06507605
- Locations
- 🇲🇱
University of Science, Technique and Technology of Bamako (Usttb), Bamako, Mali
Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV
- Conditions
- Polio ImmunizationHepatitis B ImmunizationHaemophilus Influenzae Type B ImmunizationTetanus ImmunizationDiptheria ImmunizationPertussis Immunization
- Interventions
- Biological: Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPVBiological: Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 1557
- Registration Number
- NCT06413121
- Locations
- 🇧🇩
International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh
🇮🇳Hamdard Institute of Medical Sciences and Research (HIMSR) with Centre for health research & Development, Society for applied studies, Hakeem Abdul Hameed Centenary Hospital (HAHCH), New Delhi, Delhi, India
🇮🇳Manipal Academy of Higher Education, Manipal, Mangalore, Karnataka, India
Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years
- Conditions
- Human Papillomavirus Infection
- Interventions
- Biological: Cervavac as two dose regimenBiological: Cervavac as three dose regimenBiological: Gardasil as three dose regimen
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06281119
- Locations
- 🇰🇪
Partners in Health and Research Development (Phrd), Thika, Kenya
🇰🇪Centre For Clinical Research, Kemri, Nairobi, Kenya
🇲🇿Manhiça Health Research Center - Manhiça Foundation (CISM-FM), Manhiça, Mozambique
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants
- Conditions
- Yellow Fever
- Interventions
- Biological: SII Yellow Fever VaccineBiological: STAMARIL®
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 2216
- Registration Number
- NCT05447377
- Locations
- 🇬🇲
MRC Unit The Gambia at LSHTM, Banjul, Gambia
🇲🇱Center for Vaccine Development, Bamako, Mali
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 1824
- Registration Number
- NCT05421611
- Locations
- 🇰🇪
Victoria Biomedical Research Institute (VIBRI) - Kisumu County Referral Hospital, Kisumu, Kenya
🇰🇪Kenya Medical Research Institute/ Centre for Research Disease Research (CRDR), Nairobi, Kenya
Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine
- Conditions
- Poliomyelitis
- Interventions
- Biological: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot ABiological: Sii Licensed IPVBiological: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot BBiological: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 1072
- Registration Number
- NCT05163561
- Locations
- 🇧🇩
International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh
Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age
- Conditions
- Vaccine for Meningococcal Disease
- Interventions
- Biological: NmCV-5Biological: Menactra
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 1640
- Registration Number
- NCT04358731
- Locations
- 🇮🇳
Hamdard Institute of Medical Sciences and Research (HIMSR), and Associated Hakeen Abdul Hameed Centenary Hospital (HAHCH) Jamia Hamdard, Hamdard Nagar, New Delhi - 110062, New Delhi, Delhi, India
🇮🇳Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India
🇮🇳M S Ramaiah Medical College and Hospitals, Bangalore, Bangalore, Karnataka, India
Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
- Conditions
- Mycobacterium Tuberculosis Infection
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 6940
- Registration Number
- NCT04351685
- Locations
- 🇺🇬
Medical Research Council / Uganda Virus Research Institute and London School of Hygiene and Tropical Medicines (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda
🇺🇬Makerere University/CISMAC, Kampala, Uganda
🇬🇦Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
A Phase 1 Safety Study of Dengusiil in Healthy Adults
- Conditions
- Prevention of Dengue Fever
- Interventions
- Biological: DengusiilBiological: Placebo
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04035278
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)
- Conditions
- Meningococcal Meningitis
- Interventions
- Biological: MenactraBiological: NmCV-5
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 1800
- Registration Number
- NCT03964012
- Locations
- 🇬🇲
Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, Gambia
🇲🇱Centre pour le Développement des Vaccins du Mali, ex-Institut Marchoux, Ministry of Health, BP251, Bamako, Mali